<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/Newsletter/style.css"/>
<title>Lilly&#x27;s Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, significantly improved progression-free survival in patients with treatment-naïve CLL/SLL — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/Newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">Lilly&#x27;s Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, significantly improved progression-free survival in patients with treatment-naïve CLL/SLL</h2>
    <div class="badge">2025-09-08T10:45:00+00:00</div>
    <ul>
      <li>Serious ARs occurred in 56% of patients.</li>
<li>Sepsis (6%) and febrile neutropenia (4%) occurred.</li>
<li>Mantle Cell Lymphoma Serious ARs occurred in 38% of patients.</li>
<li>The most frequent malignancy was non-melanoma skin cancer (4.6%).</li>
<li>Bleeding of any grade, excluding bruising and petechiae, occurred (17%).</li>
<li>ARs resulting in permanent discontinuation in &gt;1% of patients included pneumonia.</li>
<li>Grade 4 decreased neutrophils (14%) and Grade 4 decreased platelets (6%) developed.</li>
    </ul>
    <p>
      <a class="btn" href="https://x.com/intent/tweet?text=Lilly%27s%20Jaypirca%20%28pirtobrutinib%29%2C%20the%20first%20and%20only%20approved%20non-covalent%20%28reversible%29%20BTK%20inhibitor%2C%20significantly%20improved%20progression-free%20survival%20in%20patients%20with%20treatment-na%C3%AFve%20CLL%2FSLL%0A%E2%80%A2%20Serious%20ARs%20occurred%20in%2056%25%20of%20patients.%0A%E2%80%A2%20Sepsis%20%286%25%29%20and%20febrile%20neutropenia%20%284%25%29%20occurred.%0A%E2%80%A2%20Mantle%20Cell%20Lymphoma%20Serious%20ARs%20occurred%20in%2038%25%20of%20patients.%0A%E2%80%A2%20The%20most%20frequent%20malignancy%20was%20non-melanoma%20skin%20cancer%20%284.6%25%29.%0A%E2%80%A2%20Bleeding%20of%20any%20grade%2C%20excluding%20bruising%20and%20petechiae%2C%20occurred%20%2817%25%29.%0A%E2%80%A2%20ARs%20resulting%20in%20permanent%20discontinuation%20in%20%3E1%25%20of%20patients%20included%20pneumonia.%0A%E2%80%A2%20Grade%204%20decreased%20neutrophils%20%2814%25%29%20and%20Grade%204%20decreased%20platelets%20%286%25%29%20developed.&url=https%3A%2F%2Fsuavir600.github.io%2FNewsletter%2Farticles%2Flilly-s-jaypirca-pirtobrutinib-the-first-and-only-approved-non-covalent-reversib%2F" target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a class="btn" href="https://finance.yahoo.com/news/lillys-jaypirca-pirtobrutinib-first-only-104500259.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>